Baylor Medical Center at Garland-ko ikertzaileekin lankidetzan egindako argitalpenak (1)

2012

  1. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial

    The Lancet, Vol. 379, Núm. 9825, pp. 1498-1507